16 Amendments of Sandra PEREIRA related to 2021/2013(INI)
Amendment 57 #
B d. whereas the Declaration on the TRIPS Agreement and Public Health, adopted in Doha on14November 2001, states that the TRIPS agreement should be implemented and interpreted in a way that is good for public health – encouraging both access to existing medicines and the development of new ones; whereas the WTO TRIPS Council decided on 6 November 2015 to extend the drug patent exemption for the least developed countries (LDCs) until January 2033;
Amendment 82 #
Draft opinion
Paragraph 1 b (new)
Paragraph 1 b (new)
Amendment 87 #
Draft opinion
Paragraph 1 c (new)
Paragraph 1 c (new)
1 c. Considers that uncompetitive and monopolistic markets, as well as a lack of standardization, have contributed to supply chain shortages, notably for single use bioprocessing equipment, limiting the rapid scale-up of Covid-19 vaccine production; calls on the Commission to support intellectual property waivers and compulsory licensing of monopoly patents throughout the supply chain to address these bottlenecks;
Amendment 89 #
Draft opinion
Paragraph 1 d (new)
Paragraph 1 d (new)
1 d. Is concerned about the continuous decline in efficiency of the current innovation system due in part to data silos and the fragmentation of knowledge; calls on the Commission to promote and support open science partnerships as a mechanism to reverse declining efficiency and promote innovation, avoiding restrictive forms of intellectual property to facilitate use and sharing;
Amendment 91 #
Draft opinion
Paragraph 1 e (new)
Paragraph 1 e (new)
1 e. Recognizes the shortcomings and limited returns of the usual economic models used by the industry to develop new antibiotics; calls on the Commission to urgently present its analysis and thorough review of the current R&I incentive models in this area and address antimicrobial resistance;
Amendment 98 #
Draft opinion
Paragraph 1 i (new)
Paragraph 1 i (new)
1 i. Highlights the importance of public R&D efforts in discovering new treatments; stresses that research priorities must address public health needs, and stresses that the regulatory framework must facilitate the best possible outcome for patients and public health; calls on the Commission and the Member States to foster R&D driven by public health and unmet medical needs, including by researching new antimicrobials;
Amendment 115 #
Draft opinion
Paragraph 2 a (new)
Paragraph 2 a (new)
Amendment 145 #
Draft opinion
Paragraph 3 a (new)
Paragraph 3 a (new)
3 a. Is concerned, particularly in regard to the Innovative Health Initiative, that the Industry exercises exclusive control on the priorities of the Innovative Medicines Initiative (IMI2) Joint Undertaking, that the Industry alone draws up the strategic agendas and annual work plans and privatises the results and data of projects financed by public money;
Amendment 169 #
Draft opinion
Paragraph 4 b (new)
Paragraph 4 b (new)
4 b. Recalls that IP rights allow an extensive period of exclusivity that needs carefully and effectively to be regulated, monitored and implemented by the competent authorities so that IP rights do not limit accessibility and availability of medicines nor conflict with the fundamental human right to health;
Amendment 171 #
Draft opinion
Paragraph 4 c (new)
Paragraph 4 c (new)
4 c. Calls on the Commission to build on, extend and generalize the additional exploitation obligations, including an obligation to license on a non-exclusive basis and at fair and reasonable conditions included in the special Coronavirus calls under the Horizon 2020 Framework Programme;
Amendment 193 #
Draft opinion
Paragraph 6 a (new)
Paragraph 6 a (new)
6 a. Stresses that the high level of public funds used for R&D is not reflected in the pricing due to a lack of traceability of the public funds in the patenting and licensing conditions, impeding a fair return on public investment;
Amendment 198 #
Draft opinion
Paragraph 6 c (new)
Paragraph 6 c (new)
6 c. Notes that repurposing off-patent drugs has long been presented as a cost- effective and efficient way to develop new treatments; regrets however that a lack of publicly available data has limited its potential; insists that the repurposing of off-patent medicines not lead in any case to a decline in accessibility and that price increases would defeat the low cost of off- patent medications, a main point of interest of repurposing; highlights therefore the importance of public investment, coordination and initiative;
Amendment 211 #
7 a. Calls for EU joint procurement to be used more systematically to avoid Member States competing against each other and to ensure equal and affordable access to important medicines and medical devices, in particular for new innovative antibiotics, new vaccines and curative medicines, and medicines for rare diseases;
Amendment 230 #
Draft opinion
Paragraph 8 a (new)
Paragraph 8 a (new)
8 a. Stresses the importance of safe- guarding and creating quality jobs along the entire pharmaceutical value chain; calls on the Commission to promote equality employment in the pharmaceutical sector; considers that public funding, notably under Next Generation EU, requires employment safeguards; calls for a ban on collective redundancies in companies distributing shareholder dividends;
Amendment 248 #
Draft opinion
Paragraph 8 c (new)
Paragraph 8 c (new)
8 c. Highlights that increasing manufacturing and ‘fill and finish’ capacities requires sharing the technological know-how and intellectual property and corresponding technology; invites the Commission to encourage the transfer of crucial health technologies to developing countries by granting open licenses for such technologies in line with obligations under Article 66.2 of the TRIPS Agreement;
Amendment 269 #
Draft opinion
Paragraph 8 g (new)
Paragraph 8 g (new)